Radioactive seeds insertion with chemotherapy for advanced non‐small‐cell lung cancer: A meta‐analysis

Wu, Hong; Li, Lei; Yang, Jing; Yang, Zhimin

doi:10.1111/crj.13283

Cited by 2 publications

(14 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Percutaneous CT-guided ISB decreases the local recurrence rate of NSCLC with a few complications [ 29 ]. Therefore, many researchers have also combined ISB and first-line chemotherapy for patients with severe NSCLC [ 7 ].…”

Section: Discussionmentioning

confidence: 99%

“…When performing the CCRT, traditional external radiotherapy is commonly used [ 4 – 6 ]. However, traditional external radiotherapy is typically associated with radiation- related complications, and the radiological dosing is limited by the distance between the tumor and the surrounding healthy tissue and vital organs [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

“…Recently, I-125 seeds brachytherapy (ISB) has been widely used for the treatment of various malignant tumors [ 7 – 10 ]. Compared to the traditional external radiotherapy, ISB has many advantages, including the ease of delivery, direct interaction with the tumor surface, and the sustained application of low-dose radiation to the tumor site over a prolonged duration of time [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

“…Compared to the traditional external radiotherapy, ISB has many advantages, including the ease of delivery, direct interaction with the tumor surface, and the sustained application of low-dose radiation to the tumor site over a prolonged duration of time [ 10 ]. ISB is often used in combination with systematic chemotherapy or transcatheter arterial chemical infusion in patients with progressive NSCLC [ 7 ]. However, a majority of the previous studies focused on the combination of ISB and chemotherapy as the FLT for severe NSCLC patients [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

“…ISB is often used in combination with systematic chemotherapy or transcatheter arterial chemical infusion in patients with progressive NSCLC [ 7 ]. However, a majority of the previous studies focused on the combination of ISB and chemotherapy as the FLT for severe NSCLC patients [ 7 ]. However, the number of studies investigating the combination of ISB and chemotherapy treatment for progressive NSCLC after FLT is still limited [ 11 – 16 ].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

I-125 seeds with chemotherapy for progressive non-small-cell lung cancer after first-line treatment: a meta-analysis

Chen¹,

Fan²,

et al. 2022

J Cardiothorac Surg

View full text Add to dashboard Cite

Background Continuing therapy for aggressive non-small-cell lung cancer (NSCLC) after first-line treatment (FLT) is challenging. The clinical efficacy of second-line chemotherapy (SLCT) for progressive NSCLC is limited. In this meta-analysis, we aim to evaluate the clinical efficacy of the combination of I-125 seeds brachytherapy (ISB) and SLCT in progressive NSCLC after FLT. Methods The PubMed, Embase, Cochrane Library, CNKI, Wanfang, and VIP databases were screened for relevant publications until September 2021. Meta-analyses are conducted by RevMan 5.3 and Stata 12.0. Results Our meta-analysis encompassed 6 studies (4 retrospective studies and 2 randomized controlled trials), which included 272 patients that underwent ISB with SLCT (combined group) and 257 patients that received SLCT alone (chemotherapy alone group). The complete response (24.7% vs. 7.0%, P < 0.00001), treatment response (65.7% vs. 38.1%, P = 0.0002), and disease control (95.2% vs. 80.4%, P < 0.00001) rates are markedly elevated for patients receiving combined therapy versus those receiving chemotherapy alone. Moreover, pooled progression-free survival (P = 0.0001) and overall survival (P < 0.00001) were remarkably extended for patients that received the combination therapy, while no obvious differences were detected in the pooled myelosuppression (39.0% vs. 30.6%, P = 0.05) and gastrointestinal response (38.5% vs. 35.9%, P = 0.52) rates between 2 groups. Significant heterogeneity was found in the endpoints of the treatment response and progression-free survival. Conclusions This meta-analysis demonstrated that ISB could enhance the clinical efficacy of SLCT in patients with progressive NSCLC after FLT without inducing major toxic side effects.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

I-125 seeds with chemotherapy for progressive non-small-cell lung cancer after first-line treatment: a meta-analysis

Chen¹,

Fan²,

et al. 2022

J Cardiothorac Surg

View full text Add to dashboard Cite

show abstract

Iodine-125 seeds insertion with trans-arterial chemical infusion for advanced lung cancer: a meta-analysis

Hong¹,

Shi²,

Fu³

2022

jcb

View full text Add to dashboard Cite

Purpose: Local treatments, including iodine-125 ( 125 I) seeds insertion (ISI) and trans-arterial chemical infusion (TAI), were used for advanced non-small-cell lung cancer (NSCLC) or small-cell lung cancer (SCLC) cases. The present meta-analysis investigated the clinical efficacy of combined TAI and ISI for advanced lung cancer (LC).Material and methods: This meta-analysis was performed according to preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement. Relevant studies were searched in PubMed, Embase, Cochrane Library, CINK, Wanfang, and VIP (until October 2021) databases, using the following key words: (((((Iodine-125) OR (I125)) OR (125I)) OR (brachytherapy)) AND ((lung cancer) OR (NSCLC))) AND (chemotherapy). Outcomes included complete response rate (CRR), treatment success rate (TSR), disease control rate (DCR), 1-year survival rate, 2-year survival rate, overall survival (OS), and treatment-related toxicity. RevMan v. 5.3 and Stata v. 12.0 were applied for meta-analysis.Results: Eight studies were included in the evaluation. Three hundred and seventy-seven patients underwent combined TAI and ISI treatment (combined group), while 397 patients underwent TAI alone (TAI alone group). The pooled CRR (p = 0.001), TSR (p < 0.00001), DCR (p < 0.00001), 1-year survival rate (p < 0.00001), OS duration (p = 0.0002), and gastrointestinal reaction rate (p = 0.02) were superior in combined group. The pooled 2-year survival rate increased in combined cohort than in TAI alone group (p = 0.08). The pooled myelosuppression rates were comparable between the 2 groups (p = 0.29). Publication bias was not found in any of endpoints.Conclusions: ISI can enhance TAI clinical efficacy in clinical cases of advanced LC, excluding severe adverse events.

show abstract

Radioactive seeds insertion with chemotherapy for advanced non‐small‐cell lung cancer: A meta‐analysis

Cited by 2 publications

References 24 publications

I-125 seeds with chemotherapy for progressive non-small-cell lung cancer after first-line treatment: a meta-analysis

I-125 seeds with chemotherapy for progressive non-small-cell lung cancer after first-line treatment: a meta-analysis

Iodine-125 seeds insertion with trans-arterial chemical infusion for advanced lung cancer: a meta-analysis

Contact Info

Product

Resources

About